As of close of business last night, Adamis Pharmaceuticals Corporation’s stock clocked out at $0.12, down -0.24% from its previous closing price of $0.12. In other words, the price has decreased by -$0.0003 from its previous closing price. On the day, 1111350 shares were traded. ADMP stock price reached its highest trading level at $0.1354 during the session, while it also had its lowest trading level at $0.1200.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
To gain a deeper understanding of ADMP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.10. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 18 when Marguglio David J. sold 11,859 shares for $0.60 per share. The transaction valued at 7,117 led to the insider holds 233,906 shares of the business.
CARLO DENNIS J PHD sold 10,490 shares of ADMP for $6,287 on Mar 18. The President & CEO now owns 285,867 shares after completing the transaction at $0.60 per share. On Mar 18, another insider, Moss Ronald B., who serves as the Chief Medical Officer of the company, sold 8,199 shares for $0.60 each. As a result, the insider received 4,949 and left with 201,911 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 13.97 while its Price-to-Book (P/B) ratio in mrq is 6.22.
Stock Price History:
Over the past 52 weeks, ADMP has reached a high of $0.68, while it has fallen to a 52-week low of $0.12. The 50-Day Moving Average of the stock is 0.2078, while the 200-Day Moving Average is calculated to be 0.2725.
It appears that ADMP traded 1.26M shares on average per day over the past three months and 1.93M shares per day over the past ten days. A total of 149.98M shares are outstanding, with a floating share count of 148.38M. Insiders hold about 1.07% of the company’s shares, while institutions hold 8.70% stake in the company. Shares short for ADMP as of Jan 30, 2023 were 1.65M with a Short Ratio of 1.56M, compared to 2.51M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.10% and a Short% of Float of 1.10%.
As of right now, 0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.08. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
In the current quarter, 1 analysts expect revenue to total $1.51M. It ranges from a high estimate of $500k to a low estimate of $500k. As of the current estimate, Adamis Pharmaceuticals Corporation’s year-ago sales were $1.47M, an estimated increase of 2.80% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $1.6M, an increase of 38.10% over than the figure of $2.80% in the same quarter last year. There is a high estimate of $1.6M for the next quarter, whereas the lowest estimate is $1.6M.
A total of 1 analysts have provided revenue estimates for ADMP’s current fiscal year. The highest revenue estimate was $3.3M, while the lowest revenue estimate was $3.3M, resulting in an average revenue estimate of $3.3M. In the same quarter a year ago, actual revenue was $8.43M, down -60.80% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $9.2M in the next fiscal year. The high estimate is $9.2M and the low estimate is $9.2M. The average revenue growth estimate for next year is up 178.80% from the average revenue estimate for this year.